The transport of high amounts of vascular endothelial growth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis

Rheumatology

Volumn 48, Issue 9, 2009, Pages 1036-1044

  Solanilla, Anne ^a   Villeneuve, Julien ^a   Auguste, Patrick ^a   Hugues, Michel ^a   Alioum, Ahmadou ^b   Lepreux, Sébastien ^a   Ducroix, Jean Pierre ^c   Duhaut, Pierre ^c   Conri, Claude ^d   Viallard, Jean François ^d   Nurden, Alan T ^d   Constans, Joël ^d   Ripoche, Jean ^a  

^a INSERM   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Blood platelets; Systemic sclerosis; Vascular endothelial growth factor

Indexed keywords

AMIODARONE; ANGIOPOIETIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANTIARRHYTHMIC AGENT; BETA THROMBOGLOBULIN; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; ILOPROST; IMMUNOSUPPRESSIVE AGENT; PADGEM PROTEIN; PLATELET DERIVED GROWTH FACTOR BB; PROTON PUMP INHIBITOR; THROMBIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; ANGPT1 PROTEIN, HUMAN; ANTITHROMBOCYTIC AGENT; PLATELET DERIVED GROWTH FACTOR; PLATELET-DERIVED GROWTH FACTOR BB; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ARTICLE; CELL ASSAY; CELL ISOLATION; CELL TRANSPORT; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; MEASUREMENT; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN TRANSPORT; SYSTEMIC SCLEROSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; BLOOD; CELL CULTURE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; PROSPECTIVE STUDY; THROMBOCYTE; TRANSPORT AT THE CELLULAR LEVEL;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; BIOLOGICAL TRANSPORT; BLOOD PLATELETS; CELLS, CULTURED; FEMALE; HUMANS; ILOPROST; MALE; NEOVASCULARIZATION, PATHOLOGIC; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET-DERIVED GROWTH FACTOR; PROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70349784606     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep154     Document Type: Article

References (45)

1. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67.
2. Kahaleh MB, Sherer GK, LeRoy EC. Endothelial injury in scleroderma. J Exp Med 1979;149:1326-35.
3. Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost 2004;91:4-15.
4. Kahaleh MB, Osborn I, LeRoy EC. Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Intern Med 1982;96:610-3.
5. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
6. Harada M, Mitsuyama K, Yoshida H et al. Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 1998;27:377-80.
7. Kikuchi K, Kubo M, Kadono T, Yazawa N, Ihn H, Tamaki K. Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol 1998;139:1049-51.
8. Distler O, Del Rosso A, Giacomelli R et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002;4:R11.
9. Melder RJ, Koenig GC, Witwer BP, Safabakhsh N, Munn LL, Jain RK. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 1996;2:992-7.
10. Verheul HM, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MF, Pinedo HM. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 2000;96:4216-21.
11. Angelo LS, Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 2007;13:2825-30.
12. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
13. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
14. Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990;113:352-7.
15. LeRoy EC, Medsger TA Jr. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol 1992;10:485-8.
16. Pasquet JM, Noury M, Nurden AT. Evidence that the platelet integrin alphaIIb beta3 is regulated by the integrin-linked kinase, ILK, in a PI3-kinase dependent pathway. Thromb Haemost 2002;88:115-22.
17. Hagedorn M, Zilberberg L, Lozano RM et al. A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2. FASEB J 2001;15:550-2.
18. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992;189:824-31.
19. Goto F, Goto K, Weindel K, Folkman J. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest 1993;69:508-17.
20. Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 2006;8:1223-34.
21. Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci 1998;94: 395-404.
22. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9:685-93.
23. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005;26:587-95.
24. Distler O, Distler JH, Scheid A et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004;95:109-16.
25. Davies CA, Jeziorska M, Freemont AJ, Herrick AL. The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol 2006;37:190-7.
26. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-60.
27. Kallenberg CG, Vellenga E, Wouda AA, The TH. Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud's phenomenon. J Rheumatol 1982;9:878-84.
28. Czirjak L, Molnar I, Csipo I, Szabolcs M, Mihaly A, Szegedi G.;1; Anti-platelet antibodies against GPIIB/IIIA in systemic sclerosis. Clin Exp Rheumatol 1994;12:527-9.
29. Mohle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997;94:663-8.
30. Banks RE, Forbes MA, Kinsey SE et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998;77:956-64.
31. Zimmermann R, Koenig J, Zingsem J et al. Effect of specimen anticoagulation on the measurement of circulating platelet-derived growth factors. Clin Chem 2005;51:2365-8.
32. Handagama P, Rappolee DA, Werb Z, Levin J, Bainton DF. Platelet alpha-granule fibrinogen, albumin, and immunoglobulin G are not synthesized by rat and mouse megakaryocytes. J Clin Invest 1990;86:1364-8.
33. Pinedo HM, Verheul HM, D'Amato RJ, Folkman J. Involvement of platelets in tumour angiogenesis? Lancet 1998;352:1775-7.
34. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
35. Pepper MS, Mandriota SJ, Vassalli JD, Orci L, Montesano R. Angiogenesisregulating cytokines: activities and interactions. Curr Top Microbiol Immunol 1996;213:31-67.
36. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res 2005;97:512-23.
37. Fleming JN, Schwartz SM. The pathology of scleroderma vascular disease. Rheum Dis Clin North Am 2008;34:41-55; vi.
38. Springer ML, Chen AS, Kraft PE, Bednarski M, Blau HM. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol Cell 1998;2:549-58.
39. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000;102:898-901.
40. Dor Y, Djonov V, Abramovitch R et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J 2002;21:1939-47.
41. Krause W, Krais T. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur J Clin Pharmacol 1986;30:61-8.
42. Grant PG, Mannarino AF, Colman RW. cAMP-mediated phosphorylation of the low-Km cAMP phosphodiesterase markedly stimulates its catalytic activity. Proc Natl Acad Sci USA 1988;85:9071-5.
43. Mittag M, Beckheinrich P, Haustein UF. Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. Acta Derm Venereol 2001;81:294-7.
44. Beghetti M, Reber G, de MP et al. Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation. Eur Respir J 2002;19:518-24.
45. Medsger TA Jr. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am 2003;29:255-73; vi.